It came just hours after Novavax announced its coronavirus vaccine – of which the UK has ordered 60 million doses. It is 89 percent effective at stopping infection and 86 percent effective against the new Kent variant of the virus.
More than 43,000 people from eight countries and three regions took part in trials of the single-shot vaccine from Johnson & Johnson, which was developed by its pharmaceutical arm Janssen.
Deliveries of the Janssen jab could begin arriving in Britain in the second half of the year, provided it receives the green light from regulators.
Dr Paul Stoffels, Johnson & Johnson’s chief scientific officer, said the jab could significantly ease the burden on health services across the world, particularly as only one dose
A vaccine from Johnson & Johnson which could be delivered to the UK in the second half of this year is 66% effective against Covid-19, trial results show.
The single-shot vaccine, which has been developed by Johnson & Johnson’s pharmaceutical arm Janssen, is 66% effective overall at preventing moderate to severe Covid-19 28 days after vaccination.
The firm said the jab was 85% effective in preventing severe disease “and demonstrated complete protection against Covid-19-related hospitalisation and death as of day 28”.
This means that one month after vaccination, no one who received the vaccine was admitted to hospital or died, regardless of which strain of coronavirus they were exposed to.
A vaccine from Johnson & Johnson which could be delivered to the UK in the second half of this year is 66% effective against Covid-19, trial results show.
The single-shot vaccine, which has been developed by Johnson & Johnson’s pharmaceutical arm Janssen, is 66% effective overall at preventing moderate to severe Covid-19 28 days after vaccination.
The firm said the jab was 85% effective in preventing severe disease “and demonstrated complete protection against Covid-19-related hospitalisation and death as of day 28”.
This means that one month after vaccination, no one who received the vaccine was admitted to hospital or died, regardless of which strain of coronavirus they were exposed to.
A vaccine from Johnson & Johnson which could be delivered to the UK in the second half of this year is 66% effective against Covid-19, trial results show.
The single-shot vaccine, which has been developed by Johnson & Johnson’s pharmaceutical arm Janssen, is 66% effective overall at preventing moderate to severe Covid-19 28 days after vaccination.
The firm said the jab was 85% effective in preventing severe disease “and demonstrated complete protection against Covid-19-related hospitalisation and death as of day 28”.
This means that one month after vaccination, no one who received the vaccine was admitted to hospital or died, regardless of which strain of coronavirus they were exposed to.
A vaccine from Johnson & Johnson which could be delivered to the UK in the second half of this year is 66% effective against Covid-19, trial results show.
The single-shot vaccine, which has been developed by Johnson & Johnson’s pharmaceutical arm Janssen, is 66% effective overall at preventing moderate to severe Covid-19 28 days after vaccination.
The firm said the jab was 85% effective in preventing severe disease “and demonstrated complete protection against Covid-19-related hospitalisation and death as of day 28”.
This means that one month after vaccination, no one who received the vaccine was admitted to hospital or died, regardless of which strain of coronavirus they were exposed to.